A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆

Tarhini, Ahmad A.; Toor, Kabirraaj; Chan, Karmela Kim; McDermott, David F.; Mohr, Peter; Larkin, James; Hodi, F. Stephen; Lee, C.-H.; Rizzo, Jasmine I.; Johnson, Helen M.; Moshyk, Andriy; Rao, Sumati; Kotapati, Srividya; Atkins, Michael B.

doi:10.1016/j.esmoop.2021.100050

Cited by 17 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,9 A matching-adjusted indirect comparison demonstrated more favorable overall survival and progression-free survival benefits among patients with BRAF-mutant melanoma treated with nivolumab plus ipilimumab, compared with those treated with targeted therapy combinations, such as dabrafenib plus trametinib. 10 On the other hand, the BRAF/MEK inhibitors may be preferred in patients with rapidly progressing disease and/or symptoms, because BRAF/MEK inhibitors have a shorter time to response compared with checkpoint immunotherapies. In our patient, we selected nivolumab plus ipilimumab because BRAF V600E immunohistochemistry was negative, but nivolumab plus ipilimumab failed to elicit a response.…”

Section: Discussionmentioning

confidence: 99%

“…These regimens have dramatically improved outcomes in patients with cutaneous melanoma, especially those with BRAF V600‐mutant disease, which constitutes ~50% of metastatic cutaneous melanoma cases 8,9 . A matching‐adjusted indirect comparison demonstrated more favorable overall survival and progression‐free survival benefits among patients with BRAF ‐mutant melanoma treated with nivolumab plus ipilimumab, compared with those treated with targeted therapy combinations, such as dabrafenib plus trametinib 10 . On the other hand, the BRAF/MEK inhibitors may be preferred in patients with rapidly progressing disease and/or symptoms, because BRAF/MEK inhibitors have a shorter time to response compared with checkpoint immunotherapies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report

So¹,

Yoshida²,

Mizuno³

et al. 2022

Thoracic Cancer

View full text Add to dashboard Cite

Malignant melanoma is the most aggressive skin cancer that originates from melanocytes. Primary or metastatic pleural melanoma shares clinical and imaging characteristics with primary pleural tumors, such as pleural mesothelioma. Identification of the primary site can be challenging to distinguish between primary and secondary melanomas. We report a case of a 46‐year‐old woman with metastatic, rapidly progressing pleural melanoma mimicking primary pleural tumor. The metastatic pleural tumor from a primary cutaneous melanoma was diagnosed by reevaluating a previous surgical specimen. When evaluating patients with pleural melanoma, the primary site should be reevaluated to distinguish between primary and secondary melanomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report

So¹,

Yoshida²,

Mizuno³

et al. 2022

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…The association of cobimetinib (a MEK inhibitor) and vemurafenib (a BRAF inhibitor) has been FDA approved as standard treatment for patients with BRAF V600 -mutated melanoma. Clinical data pooled from the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies, involving patients treated with vemurafenib or cobimetinib plus vemurafenib, have demonstrated the combination therapy to be more effective in terms of tumor reduction and progression-free survival, supporting the combination BRAF and MEK inhibition as a standard of care in this disease setting [ 44 ]. Moreover, the association of the BRAF inhibitor dabrafenib (at a dose of 150 mg twice daily) plus the MEK inhibitor trametinib (2 mg once daily) studied in the COMBI-d and COMBI-v trials also showed excellent results leading to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with BRAF V600E or V600K mutation.…”

Section: Methodsmentioning

confidence: 99%

Looking into a Better Future: Novel Therapies for Metastatic Melanoma

Villani

Scalvenzi

Fabbrocini

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Even though melanoma represents a small percentage of all cutaneous cancers, it is responsible for most deaths from skin neoplasms. In early stages it can be successfully treated with surgery, but as the disease expands the survival rate drops significantly. For many years the mainstay of treatment for metastatic melanoma was chemotherapeutic agents, even though they failed to prove survival prolongation. After the advent of ipilimumab, a survival benefit and better overall response rate could be offered to the patients. Other new therapies, such as immunotherapies, targeted therapies, vaccines, and small molecules, are currently being studied. Also, combination regimens have demonstrated superiority to some monotherapies. Nowadays, ipilimumab should no longer be considered the first-line therapy given its severe toxicity and lower efficacy, while nivolumab remains efficacious and has a good safety profile. T-VEC as monotherapy has been shown to be an elegant alternative even for the elderly or cases of head and neck melanomas. If the BRAF mutation status is positive, the combination of dabrafenib and trametinib could be an option to consider. Despite the success of the novel treatments, their effectiveness is still limited. New studies have opened up new avenues for future research in melanoma treatment, which is expected to lead to better therapeutic outcomes for our patients. The objective of this review is to discuss the novel therapies for metastatic melanoma that have been tested in humans during the last 3 years to obtain a sharper perspective of the available treatment options for specific patient characteristics.

show abstract

“…Jedoch zeigen Metaanalysen die Überlegenheit der Kombinations-Immuntherapie, gefolgt von der PD-1-Inhibitortherapie gegenüber Dabrafenib/Trametinib, gefolgt von Dabrafenib mono [47] bzw. die Überlegenheit der Kombinations-Immuntherapie gegenüber allen zielgerichteten Kombinationen [48] in Bezug auf PFS und OS. Im Vergleich der Kaplan-Meier-Kurven wird bei den Immuntherapien insbesondere im PFS der frühe steile Abfall der Kurven als Zeichen für primäre Therapieresistenz und das folgende lange Plateau als Zeichen für eine langfristige/anhaltende Krankheitskontrolle deutlich.…”

Section: Zielgerichtete Therapieunclassified

Die Systemtherapie des malignen Melanoms

Ritter

Peeken

Schultz

et al. 2022

Aktuelle Dermatologie

View full text Add to dashboard Cite

ZusammenfassungIn den vergangenen 10 Jahren wurde die Systemtherapie des malignen Melanoms durch die Zulassung neuer Substanzen revolutioniert. In der vorliegenden Übersicht werden zunächst die aktuellen adjuvanten Therapiemöglichkeiten beschrieben, anschließend werden der Kenntnisstand zur neoadjuvanten Therapie dargestellt und schließlich die Behandlungsoptionen im inoperablen Stadium beleuchtet.

show abstract

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆

Cited by 17 publications

References 30 publications

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report

Looking into a Better Future: Novel Therapies for Metastatic Melanoma

Die Systemtherapie des malignen Melanoms

Contact Info

Product

Resources

About